Empirical Asset Management LLC Reduces Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Empirical Asset Management LLC decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,420 shares of the medical research company’s stock after selling 199 shares during the quarter. Empirical Asset Management LLC’s holdings in Charles River Laboratories International were worth $262,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of CRL. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Marshall Wace LLP lifted its stake in Charles River Laboratories International by 24.6% in the 2nd quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after buying an additional 163,056 shares in the last quarter. 1832 Asset Management L.P. acquired a new stake in Charles River Laboratories International during the 2nd quarter valued at $33,053,000. Finally, Earnest Partners LLC increased its position in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 1.2 %

Shares of NYSE CRL opened at $163.77 on Monday. The stock has a fifty day moving average price of $190.64 and a 200 day moving average price of $198.40. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12-month low of $160.85 and a 12-month high of $275.00. The company has a market cap of $8.37 billion, a P/E ratio of 20.50, a P/E/G ratio of 6.62 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the business posted $2.72 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Analyst Ratings Changes

CRL has been the topic of a number of analyst reports. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. William Blair reiterated an “outperform” rating on shares of Charles River Laboratories International in a report on Tuesday, January 14th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Finally, TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and a consensus target price of $209.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).